BIODANE PHARMA A/S: Financial statements 2021
CVR: 28310102
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
BIODANE PHARMA A/S (CVR 28310102) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 3,701,319 and a net result of DKK 1,897,649 compared with DKK 499,535 the year before. That is an increase of 127.2% compared with the year before. Equity in the 2021 report amounted to DKK 4,056,164. The solvency ratio was 80.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 3,701,319
- Profit/Loss
- DKK 1,897,649
- Equity
- DKK 4,056,164
- Total Assets
- DKK 5,033,419
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 3.7 mio. | 1.9 mio. | 4.1 mio. | 1 |
| 2020 | - | 1.6 mio. | 500 t. | 2.2 mio. | 1 |
| 2019 | - | 1.5 mio. | 257 t. | 1.7 mio. | 1 |
| 2018 | - | 1 mio. | -467 t. | 1.4 mio. | 1 |
| 2017 | - | 968 t. | 103 t. | 1.9 mio. | 1 |
Official annual report
Find more companies like BIODANE PHARMA A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
BIODANE PHARMA A/S has published its annual report for 2020. Gross profit came to DKK 1,628,847, and the net result was DKK 499,535.
About BIODANE PHARMA A/S
BIODANE PHARMA A/S is a Danish company of the type Aktieselskab based in Gesten, founded in 2004. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named BIODANE PHARMA ApS and BIOFIBER TØRRING ApS. The management consists of Gunner Kreutzer Jakobsen. The board consists of Peter Gæmelke (chair), Flemming Torben Heden Knudsen, Gunner Kreutzer Jakobsen and Rasmus Juhl Rasmussen. The company is owned by BIODAN A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 2,534,166 and a net result of DKK 182,862 compared with DKK 1,651,356 the year before. Equity in the 2025 report amounted to DKK 2,505,002.